Dr. Nicholas Richardson Takes a Major Step
A leader previously at the FDA's Oncology Center of Excellence, Dr. Richardson brings a wealth of experience in developing therapies for blood cancers.
A New Era at Precision for Medicine
Precision for Medicine has announced the appointment of Dr. Nicholas Richardson, DO, MPH, as Vice President of Clinical Development. With a strong background in pediatric hematology and oncology, Dr. Richardson was instrumental in overseeing the development of therapeutics aimed at combatting hematologic malignancies, including lymphoma and chronic lymphocytic leukemia.
Dr. Richardson's Proven Track Record
During his tenure at the FDA, spanning over nine years, Dr. Richardson gained a profound understanding of regulatory strategies, particularly in the development of CAR-T cell therapies and bispecifics. His experience positions him uniquely to assist clients in navigating the ever-evolving regulatory landscape regarding blood cancers.
A Vision for Innovative Therapies
Dr. Harpreet Singh, Chief Medical Officer at Precision for Medicine, expressed excitement about Dr. Richardson joining the team. “Dr. Richardson is a leader known for his innovative trial designs and in-depth knowledge of biomarkers and cell therapies.”
Transforming Blood Cancer Treatments
Dr. Richardson has spearheaded efforts to develop new endpoints in blood cancer research, such as minimal residual disease (MRD) markers for lymphoma and CLL. This innovation accelerates drug development and bridges the expertise between hematologic malignancies and solid tumor therapies within the organization.
Your Lifeline to Effective Treatments
In Dr. Richardson's own words, “My career has been dedicated to transforming the blood cancer treatment landscape, ensuring safe therapies reach patients.” At Precision for Medicine, he aims to leverage industry talent and expertise to expedite the drug development process, empowering manufacturers to deliver life-saving treatments quickly and efficiently.
About Precision for Medicine
Precision for Medicine stands as a pioneer in biomarker-driven clinical research and development support for life sciences. The organization emphasizes a transformative clinical research approach, integrating clinical trial design with comprehensive scientific knowledge. That integration fosters advanced data intelligence, driving the speed of clinical development and approval.
With its presence in North America, Europe, and Asia-Pacific, Precision for Medicine employs approximately 3,600 individuals, dedicated to providing unmatched support to clients in the pursuit of effective, targeted therapies.
Frequently Asked Questions
Who is Nicholas Richardson?
Nicholas Richardson is an experienced physician and leader in the field of pediatric hematology and oncology who has recently joined Precision for Medicine as VP of Clinical Development.
What role did Dr. Richardson previously hold?
Dr. Richardson served as Deputy Director of the Division of Hematologic Malignancies 2 at the U.S. Food and Drug Administration.
Why is Dr. Richardson's experience important?
His extensive background in regulatory strategy and innovative trial designs is vital for guiding clients in the development of therapies for hematologic malignancies.
What is Precision for Medicine’s mission?
Precision for Medicine focuses on advancing biomarker-driven clinical research to improve the precision of treatments offered to patients.
How many employees does Precision for Medicine have?
The company employs around 3,600 individuals globally across various regions.
